<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02405065</url>
  </required_header>
  <id_info>
    <org_study_id>HM-RAFI-101</org_study_id>
    <nct_id>NCT02405065</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573</brief_title>
  <official_title>Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573 in Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to determine the maximum tolerated dose (MTD) and&#xD;
      recommended phase 2 dose of HM95573.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Besides the main objective, there are 3 other objectives as follows:&#xD;
&#xD;
        -  To evaluate the anti-cancer effect of HM95573 in solid tumor patients&#xD;
&#xD;
        -  To investigate the pharmacokinetic profile of HM95573 after oral administration.&#xD;
&#xD;
        -  To investigate biomarkers related to the safety and efficacy of HM95573.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 12, 2015</start_date>
  <completion_date type="Actual">May 16, 2018</completion_date>
  <primary_completion_date type="Actual">January 18, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Dose limiting Toxicity will be evaluated on Day 28 during Cycle 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall rsponse rate</measure>
    <time_frame>6-12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>HM95573</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM95573</intervention_name>
    <description>BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops</description>
    <arm_group_label>HM95573</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be 20 years of age or older&#xD;
&#xD;
          -  Subjects who have provided voluntary consent to participate in the study, and signed&#xD;
             the written consent document.&#xD;
&#xD;
          -  Estimated life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Histologically or cytologically confirmed advanced solid tumor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptomatic or uncontrolled central nervous system metastases&#xD;
&#xD;
          -  Patients who are unable to take tablets orally or have a clinically significant&#xD;
             gastrointestinal disorder, which may interfere with administration, metabolism and&#xD;
             absorption of the investigational drug.&#xD;
&#xD;
          -  Patients who, in the investigator's opinion, are not suitable for the study for any&#xD;
             other reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yohan Kim, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hanmi Pharmaceutical co., ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hanmi Clinical</name>
      <address>
        <city>Seoul</city>
        <zip>05545</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 15, 2015</study_first_submitted>
  <study_first_submitted_qc>March 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2015</study_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

